Riverbridge Partners LLC Cuts Stock Position in Certara, Inc. (NASDAQ:CERT)

Riverbridge Partners LLC reduced its stake in Certara, Inc. (NASDAQ:CERT - Free Report) by 9.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,164,747 shares of the company's stock after selling 236,171 shares during the quarter. Riverbridge Partners LLC owned about 1.34% of Certara worth $23,055,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in the stock. The Manufacturers Life Insurance Company boosted its position in shares of Certara by 4.5% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 22,871 shares of the company's stock worth $317,000 after purchasing an additional 975 shares in the last quarter. Nicolet Advisory Services LLC boosted its position in shares of Certara by 6.6% in the 3rd quarter. Nicolet Advisory Services LLC now owns 24,831 shares of the company's stock worth $273,000 after purchasing an additional 1,531 shares in the last quarter. KBC Group NV boosted its position in shares of Certara by 48.2% in the 3rd quarter. KBC Group NV now owns 4,873 shares of the company's stock worth $57,000 after purchasing an additional 1,584 shares in the last quarter. Blue Trust Inc. boosted its position in shares of Certara by 112.3% in the 3rd quarter. Blue Trust Inc. now owns 3,925 shares of the company's stock worth $46,000 after purchasing an additional 2,076 shares in the last quarter. Finally, Everence Capital Management Inc. boosted its position in shares of Certara by 21.0% in the 3rd quarter. Everence Capital Management Inc. now owns 14,910 shares of the company's stock worth $175,000 after purchasing an additional 2,590 shares in the last quarter. 73.96% of the stock is owned by institutional investors.

Certara Stock Performance

CERT traded up $0.17 during mid-day trading on Thursday, reaching $13.16. 596,658 shares of the company traded hands, compared to its average volume of 1,040,562. The stock has a market capitalization of $2.12 billion, a P/E ratio of -65.78, a P/E/G ratio of 9.48 and a beta of 1.52. The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.28. The company's fifty day moving average price is $11.01 and its 200-day moving average price is $11.89. Certara, Inc. has a 52-week low of $9.41 and a 52-week high of $19.87.

Certara (NASDAQ:CERT - Get Free Report) last announced its earnings results on Wednesday, November 6th. The company reported $0.13 earnings per share for the quarter, beating analysts' consensus estimates of $0.11 by $0.02. The business had revenue of $94.80 million during the quarter, compared to analyst estimates of $95.51 million. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. The company's quarterly revenue was up 10.7% compared to the same quarter last year. During the same period in the previous year, the business earned $0.06 EPS. On average, sell-side analysts expect that Certara, Inc. will post 0.28 EPS for the current year.

Analyst Upgrades and Downgrades

CERT has been the topic of several analyst reports. UBS Group raised Certara from a "neutral" rating to a "buy" rating and set a $16.00 price objective on the stock in a research report on Friday, September 27th. Barclays lowered their price objective on Certara from $14.00 to $12.00 and set an "equal weight" rating on the stock in a research report on Thursday, November 7th. Finally, Robert W. Baird lowered their price objective on Certara from $18.00 to $13.00 and set a "neutral" rating on the stock in a research report on Tuesday, November 5th. Six investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $15.92.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.